Donald Lehr Sells 29,131 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) insider Donald Lehr sold 29,131 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total value of $127,011.16. Following the completion of the transaction, the insider owned 755,461 shares in the company, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Stock Performance

NASDAQ PGEN opened at $3.86 on Wednesday. The company has a market cap of $1.38 billion, a PE ratio of -3.27 and a beta of 1.06. The stock’s 50 day simple moving average is $4.04 and its 200-day simple moving average is $4.10. Precigen, Inc. has a 1-year low of $1.28 and a 1-year high of $5.47. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12.

Precigen (NASDAQ:PGEN) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. As a group, equities research analysts anticipate that Precigen, Inc. will post 0.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HC Wainwright raised their target price on Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Wall Street Zen cut Precigen from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $12.50.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Wyoming acquired a new stake in Precigen during the first quarter worth $27,000. NBC Securities Inc. acquired a new stake in Precigen during the fourth quarter worth $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Precigen during the third quarter worth $39,000. Royal Bank of Canada increased its stake in Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,426 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Precigen during the third quarter worth $41,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.